Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 10c

Roth Affirms Ligand Pharma (LGND) at 'Buy'; Captisol, Promacta Lead Strong Q1 Results

May 7, 2014 11:49 AM EDT

Roth Capital is commenting on Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) following the company's Q1 report. Roth has Ligand at Buy with a price target of $92.

Earlier, Ligand reported Q1 EPS of $0.35, $0.10 better than the analyst estimate of $0.25. Revenue for the quarter came in at $16 million versus the consensus estimate of $13.63... More